Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 3/20 | 0.36 |
| ▸ | TGM2 | P21980 | 3/20 | 0.36 |
| ▸ | TGM1 | P22735 | 3/20 | 0.36 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6896840 | 0.96 | PKM (0.37) | F13A1TGM2TGM1TGM3MAPT | |
| SCHEMBL5742053 | 0.94 | F13A1 (0.37) | F13A1TGM2TGM1TGM3MAPT | |
| SCHEMBL6896236 | 0.91 | UTS2R (0.37) | F13A1TGM2TGM1TGM3MAPT | |
| SCHEMBL6895758 | 0.88 | TGM2 (0.36) | F13A1TGM2TGM1TGM3MAPT | |
| SCHEMBL6893668 | 0.86 | ALDH1A1 (0.35) | MAPT | |
| SCHEMBL6892977 | 0.85 | UTS2R (0.41) | F13A1TGM2TGM1TGM3MAPT | |
| SCHEMBL5742580 | 0.83 | UTS2R (0.37) | F13A1TGM2TGM1TGM3MAPT | |
| SCHEMBL5734380 | 0.82 | TGM2 (0.48) | F13A1TGM2TGM1TGM3MAPT | |
| Hydrochloric Acid SCHEMBL6895332 | 0.81 | F10 (0.34) | — | |
| SCHEMBL5741347 | 0.81 | STS (0.40) | F13A1TGM2TGM1MAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109200-B2 | Carbamate derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-19 | — | — | US | disclosed |
| EP-1340753-B1 | CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20040038986-A1 | Carbamate derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1340753-A1 | CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038986-A1 | Carbamate derivatives, process for producing the same and use thereof | CFH, F11, F2 | F13A1 18/4885TGM2 1508/4885TGM1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.